CAJ | 학술논문

目的：探讨齐拉西酮与利培酮治疗首发精神分裂症患者的疗效和安全性。方法将56例首发精神分裂症患者随机分为两组，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（ P＜0．05或0．01），治疗第4周、6周末研究组阴性症状因子分较对照组下降更显著（ P＜0．05或0．01）；治疗6周末两组显效率、有效率比较差异无显著性（P＞0．05）。两组不良反应均轻微，但研究组体质量增加发生率显著低于对照组（P＜0．01）。结论齐拉西酮与利培酮治疗首发精神分裂症疗效显著且相当，安全性高，但齐拉西酮改善阴性症状效果更显著，对体质量无明显影响，更有利于提高患者的治疗依从性。
목적：탐토제랍서동여리배동치료수발정신분렬증환자적료효화안전성。방법장56례수발정신분렬증환자수궤분위량조，연구조구복제랍서동치료，대조조구복리배동치료，관찰6주。우치료전후채용양성여음성증상량표평정림상료효，부반응량표평정불량반응。결과치료후량조양성여음성증상량표총분급각인자분균교치료전유현저하강（ P＜0．05혹0．01），치료제4주、6주말연구조음성증상인자분교대조조하강경현저（ P＜0．05혹0．01）；치료6주말량조현효솔、유효솔비교차이무현저성（P＞0．05）。량조불량반응균경미，단연구조체질량증가발생솔현저저우대조조（P＜0．01）。결론제랍서동여리배동치료수발정신분렬증료효현저차상당，안전성고，단제랍서동개선음성증상효과경현저，대체질량무명현영향，경유리우제고환자적치료의종성。
Objective To explore the efficacy and safety of ziprasidone and risperidone in the treatment of first‐episode schizophrenia .Methods Fifty‐six first‐episode schizophrenics were randomly divided into two groups ,research group took orally ziprasidone and control group did risperidone for 6 weeks .Clinical effi‐cacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment to‐tal and each factor scores of the PANSS of both groups lowered more significantly compared with pretreat‐ment(P<0 .05 or 0 .01) ,so did negative symptom scores in research than control group at the end of the 4th and 6th week (P<0 .05 or 0 .01);there were no significant group differences in obvious effective and ef‐fective rate at the end of the 6th week (P>0 .05) .Adverse reactions of both groups were mild ,but the in‐cidence of weight gain was significantly lower in research than control group (P<0 .01) .Conclusion Zi‐prasidone equivalent to risperidone has an evident effect and higher safety in first‐episode schizophrenia , but it improves negative symptoms more notably ,has no influence on body mass ,is beneficial to the im‐provement of treatment compliance .